Kangbao Bio breaks ground on vaccine plant
Shanghai. May 20. INTERFAX-CHINA - Shanxi Kangbao Biological Products Co. Ltd. (Kangbao Bio) has begun building a vaccine production plant in Changzhi City, Shanxi Province, a senior employee told Interfax May 20.
Kangbao Bio plans to spend a total of RMB 200 million ($30.76 million) on the 100,000 square-meter facility located in Changzhi High and New Technology Zone, said Shen Yunfei, the company's chief engineer. The facility is slated for completion in two to three years, Shen added.
The plant has a designed annual production capacity of 10 million doses of malaria vaccine, 10 million doses of dust mite allergy vaccine, 8 million doses purified rabies vaccine for human use, and 40 million doses of vaccine for Helicobacter pylori (H. pylor), a type of bacteria that can cause digestive diseases.
In March last year, Kangbao Bio entered into a RMB 30 million ($4.61 million) deal with the Beijing-based Academy of Military Medical Sciences to jointly develop the H. pylor vaccine, a class one new drug, the company previously announced.
Based in Changzhi City, privately-owned Kangbao Bio mainly produces blood products and chemical medicines. The company generated sales revenue over RMB 1 billion ($153.8 million) in 2010, according to its website.
- MS